Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
To estimate the efficacy of nab-paclitaxel administered intravenously (IV) on Days 8 and 15 with epigenetic modifying therapy of CC-486 once daily (QD) on Days 1 to 14 every 21 days or nab-paclitaxel administered intravenously (IV) on Days 1 and 8 with immunotherapy of durvalumab administered IV on Day 15 every 21 days, and nab-paclitaxel monotherapy administered IV on Days 1 and 8 every 21 days as second/third-line treatment for advanced NSCLC.
Critère d'inclusion
- Advanced non-small cell lung cancer (NSCLC)